Dayle Hogg
InvestorManaging Director at International Finance Corporation · Operating Executive at Abingworth
London, England, United Kingdom
Find your path to Dayle
463 people in our graph share verified history with Dayle — schools, employers, funds. One of them is your warm intro.
Sofia DahouneunlockedDayle: together at International Finance Corporation (2025)
×7Dayle: together at University of Leeds
×4Dayle: together at International Finance Corporation
About
Dayle Hogg joined Abingworth in March 2023 to support the operational capabilities of portfolio companies. He was previously COO of GammaDelta Therapeutics until its 2022 acquisition by Takeda, cofounder of Adaptate Biotherapeutics, COO of Kesios Therapeutics, and an investment manager at Touchstone Innovations, and he cofounded Lectus Therapeutics. He holds a degree in Pharmacology from the University of Leeds and a PhD in Pharmacology from the University of Oxford.
Invests in
Biotech
Experience
- AbingworthOperating Executivecurrent2023 — present
- TakedaHead, Gamma Delta Operations2022
- GammaDelta TherapeuticsChief Operating Officer2017 — 2022London Area, United Kingdom
- Kesios TherapeuticsChief Operating Officer2015 — 2017London Area, United Kingdom
- Kesios TherapeuticsInterim Operations Director2015London Area, United Kingdom
- Kesios TherapeuticsNon Executive Director2012 — 2015London Area, United Kingdom
- Imperial InnovationsHealthcare Ventures Manager2011 — 2015London Area, United Kingdom
- Calcico TherapeuticsNon Executive Director2013 — 2015Greater Oxford Area
- Lectus Therapeutics LimitedCommercial Vice President2003 — 2011Greater Cambridge Area
- Sense Proteomic LimitedBusiness Development Associate2002Greater Cambridge Area
- University of BristolPostdoctoral Research Assistant, Dept of Pharmacology2001 — 2002Greater Bristol Area, United Kingdom
- University of OxfordPostdoctoral Research Assistant, Dept of Pharmacology2001Greater Oxford Area
Skills & more
Drug Discovery20Biotechnology7Lifesciences5Pharmacology9Drug Development9Biochemistry5Clinical Development4Pharmaceutical Industry6Oncology3Cell Biology3Neuroscience3Science2
+7 more
CommercializationR&DClinical TrialsImmunologyRegulatory AffairsCell CultureLife SciencesFrom Dayle's professional profile.
Investments
Led
Enterprise TherapeuticsStorm Therapeutics
Per the firm's website.
Colleagues at International Finance Corporation
Aaron Pollock
Partner at SWaN & Legend Venture Partners
Adele Teh
Investor at Openspace Capital Pte. Ltd.
Alfonso García Mora
Regional Vice President, Europe, Latin America and the Caribbean at International Finance Corporation
Dr. Amit N. Thakker
Africa Healthcare Adviser at Asia Africa Investment & Consulting (AAIC)
Elena Bourganskaia
Vice President, Strategy and Operations Support at International Finance Corporation
Ethiopis Tafara
Regional Vice President, Africa at International Finance Corporation
Federico Galizia
IFC Vice President and Chief Risk Officer at International Finance Corporation
John Gandolfo
Vice President and Chief Financial Officer at International Finance Corporation
Frequently asked questions
- Who is Dayle Hogg?
- Dayle Hogg joined Abingworth in March 2023 to support the operational capabilities of portfolio companies. He was previously COO of GammaDelta Therapeutics until its 2022 acquisition by Takeda, cofounder of Adaptate Biotherapeutics, COO of Kesios Therapeutics, and an investment manager at Touchstone Innovations, and he cofounded Lectus Therapeutics. He holds a degree in Pharmacology from the University of Leeds and a PhD in Pharmacology from the University of Oxford.
- Where does Dayle Hogg work?
- Dayle Hogg is Managing Director at International Finance Corporation.
- What does Dayle Hogg invest in?
- Dayle Hogg invests in Biotech.
- What companies has Dayle Hogg invested in?
- Investments tracked here include Enterprise Therapeutics, Storm Therapeutics.
- Where did Dayle Hogg go to school?
- Dayle Hogg studied at University of Oxford (PhD, Pharmacology); University of Leeds (BSc, Pharmacology).
- Does Dayle Hogg lead rounds?
- Yes — Dayle Hogg has led 2 tracked investments.
Same school
Also attended University of Oxford1,752
Reid HoffmanCo-founder of LinkedIn; Partner at GreylockMichael MoritzFormer Partner at Sequoia Capital; Senior Adviser at Sequoia HeritageGabriel PereyraCo-founder & President of HarveyDominic JacquessonInvestor at Index VenturesErin Price-WrightInvestor at Index VenturesJan HammerInvestor at Index Ventures
+ 1,746 more
Also attended University of Leeds228
Joseph StolermanInvestor at Index VenturesLaura CliffordTalent Director at NorthzoneJason MorrisVice President, Investor Relations at Sapphire VenturesIan MilbournGeneral Partner & COO at Notion CapitalJohn MesrieOperating Partner at Inreach VenturesPhil TomkinsonFinance & Portfolio Associate at Giant Ventures Global Llp
+ 222 more
Shared employers
Also worked at Takeda76
Rebecca RedfieldSenior Associate at .406 VenturesAtsushi ShimadaSenior Principal at AN Venture PartnersDai HataAssociate at AN Venture PartnersJulie KimRepresentative Director – President and CEO at Takeda VenturesAkiko AmakawaCEO Chief of Staff at Takeda VenturesAsuka MiyabashiraPresident, Japan Pharma Business Unit at Takeda Ventures
+ 70 more
Also worked at GammaDelta Therapeutics1
Also worked at Imperial Innovations10
Oliver SextonInvestment Director at Future Planet CapitalInga DeakinPrincipal at Molten VenturesSarah JonesPrincipal at Zero Carbon CapitalGraham O'KeeffeExternal Advisor at EBRD Venture Capital Investment ProgrammeDomFounding Director at Deep Science VenturesEliot CharlesPartner at Apax Digital
+ 4 more
Also worked at University of Bristol62
Saran DaviesInvestor at Moonfire VenturesCharles GrummittInvestor at MedicxiSimon PorterPrincipal at Blackfinch VenturesPoppy RussellResearch Manager at Counteract OneHannah MaunderInvestor Relations and Communications Associate at SV Health InvestorsEmily BullmanInvestor at JamJar Investments
+ 56 more